Pharma channel feed

Sen­a­tors call on FDA to not risk bi­as­ing study find­ings in fa­vor of opi­oid use

Last year

Dex­com re­cruits new class of col­lege ath­letes with type 1 di­a­betes for spon­sor­ship deals

Last year
Marketing

FDA ad­vi­sors unan­i­mous­ly re­ject Intar­ci­a's em­bat­tled type 2 di­a­betes treat­ment

Last year
FDA+

Roche scru­ti­nized by UK watch­dog over 'mis­lead­ing' Ro­z­lytrek pro­mo­tion­al web­site

Last year
Marketing

GE Health­Care hits the road in a health tech bus to bring its lat­est so­lu­tions to hos­pi­tal doorsteps

Last year
Marketing

GSK's Vi­iV Health­care takes Shut­ter­stock-part­nered cam­paign in new di­rec­tion

Last year
Marketing

Ex­clu­sive: As­traZeneca signs off on a ‘car­bon neg­a­tive’ new biotech build­ing for one of its lat­est buy­outs

Last year
Bioregnum

No­vo Nordisk’s US semaglu­tide man­u­fac­tur­ing site un­der the spot­light again as 2022 mon­i­tor­ing is­sue sur­faces

Last year
Manufacturing

Physi­cians see ‘new era for weight loss med­ica­tions’ with the ar­rival of No­vo, Lil­ly GLP-1 meds, sur­vey says

Last year
Marketing

Ac­tor Er­ic Ston­estreet talks about his re­al 'mod­ern fam­i­ly' in aware­ness cam­paign for eye dis­ease

Last year
Marketing

Mod­er­na de­creas­es mR­NA pro­duc­tion with Lon­za in Switzer­land, brings some man­u­fac­tur­ing in-house

Last year
Manufacturing

In­cyte ad­vances its Opzelu­ra eczema cam­paign with a ‘reimag­ine’ theme  

Last year
Marketing

Elon Musk's brain-com­put­er pro­gram be­gins re­cruit­ing paral­y­sis pa­tients

Last year
R&D
FDA+

FDA un­der­scores qual­i­ty, safe­ty con­cerns with Intar­cia’s di­a­betes treat­ment ahead of ad­comm

Last year
FDA+

It’s al­most the end of the road for Fresh Tracks as board sup­ports liq­ui­da­tion

Last year
People

Ther­mo Fish­er is ready to ex­pand its vi­ral vec­tor pro­duc­tion site in Mass­a­chu­setts once there’s ‘de­mand for it’

Last year
Manufacturing

Eli Lil­ly sues com­pounders and med­ical spas over sales of un­ap­proved copy­cats of its di­a­betes block­buster Moun­jaro

Last year
Law

House law­mak­ers press CMS on mon­i­tor­ing re­bate in­for­ma­tion, tout PBM re­forms at hear­ing

Last year
FDA+

Al­ler­gan on the hook for $160M for hy­dro­cor­ti­sone ‘abuse of dom­i­nance,’ UK court rules

Last year
Law

Heron Ther­a­peu­tics launch­es patent suit against My­lan over po­ten­tial gener­ic for chemo-re­lat­ed nau­sea

Last year
Law

Two phar­ma­cy ben­e­fit man­ag­er stud­ies find in­creas­ing fees and de­clin­ing opin­ions as House con­sid­ers ac­tion

Last year
Marketing

Mar­ket­ingRx roundup: Ab­bott teams with Weight­Watch­ers for glu­cose mon­i­tor­ing; Ha­le­on’s Advil starts ‘pain eq­ui­ty’ ef­fort

Last year
Marketing

Q&A: Gilead pub­lic af­fairs chief on new strat­e­gy, Tik­Tok, and why the com­pa­ny won’t ‘keep do­ing things the same way’ 

Last year
Marketing

Iver­ic, Astel­las eye US la­bel ex­pan­sion for ge­o­graph­ic at­ro­phy drug af­ter pos­i­tive two-year da­ta

Last year
R&D
First page Previous page 99100101102103104105 Next page Last page
A service from the Financial Times